title: Characterization of antibody-drug conjugates by mass spectrometry: advances and future trends.
abstract: Antibody-drug conjugates (ADCs) are emerging modalities in the pharmaceutical industry. The unique target-specific binding of antibody allows targeted delivery of cytotoxic small molecules to cancer cells, and thus expands the therapeutic window. However, in-depth characterization of ADCs is complex because it involves the characterization of antibody, conjugated molecules and antibody conjugates as a whole. In this review, we describe the practical use of mass spectrometry for ADC characterization including qualitative and quantitative analysis. Technical advances, limitations and future trends will also be discussed.
authors.affiliation: Bioanalytical and Discovery Analytical Sciences, Research and Development, Bristol-Myers Squibb, Route 206 & Province Line Road, Princeton, NJ 08543, USA.
authors.forename: Richard Y-C
authors.initials: RY
authors.lastname: Huang
authors.affiliation: Bioanalytical and Discovery Analytical Sciences, Research and Development, Bristol-Myers Squibb, Route 206 & Province Line Road, Princeton, NJ 08543, USA. Electronic address: guodong.chen@bms.com.
authors.forename: Guodong
authors.initials: G
authors.lastname: Chen
mesh_terms: D000911:Antibodies, Monoclonal / Q000737:chemistry*; D018796:Immunoconjugates / Q000737:chemistry*; D013058:Mass Spectrometry; D004364:Pharmaceutical Preparations / Q000737:chemistry*
chemical_list: D000911:Antibodies, Monoclonal; D018796:Immunoconjugates; D004364:Pharmaceutical Preparations